Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 16,401 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Central Nervous System Disorder Clear all

Conditions: High Risk Meningioma, Recurrent Meningioma
Interventions: ⁶⁸Ga-Dotatate PET and MRI Guided Radiation Therapy, Magnetic Resonance Imaging (MRI), 68Ga-Dotatate PET Imaging, MD Anderson Symptom Inventory Bain Tumor form (MDASI-BT), EuroQol-5 Dimension (ED-5D); Radiation · Diagnostic Test · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Parkinson Disease
Interventions: exercise+multi-modal sensory feedback (MMSF), Exercise only; Behavioral
Lead sponsor: Regis University; Other
Eligibility: 21 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Brain Tumor, Brain Neoplasms, Brain Cancer, Glioma, Glioblastoma
Interventions: Ultrasound; Diagnostic Test
Lead sponsor: Hospital del Rio Hortega; Other
Eligibility: 15 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Focal Epilepsy
Interventions: Acoustic Stimulation (AS), SHAM Stimulation; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Mild Cognitive Impairment, Alzheimer Disease
Interventions: Spironolactone, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 50 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Depression, Anxiety
Interventions: IntelliCare, Hub App with the Recommender System, Coaching; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atherosclerosis, Stroke
Interventions: Carotid Ultrasound; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 40 Years to 70 Years
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 5
States / cities: Fort Atkinson, Wisconsin • Janesville, Wisconsin • Oconomowoc, Wisconsin + 2 more

Conditions: Stroke, Hemiparesis
Interventions: Active rTMS, Sham rTMS, Open Placebo; Device · Dietary Supplement
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Fabry Disease
Interventions: migalastat HCl, ERT; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 5 more

Conditions: Covid19, Androgen Receptor Gene Overexpression
Interventions: COVID-19 Androgen Sensitivity Test (CoVAST); Genetic
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 90 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Irvine, California

Conditions: Alcohol Dependence, Alcohol Use Disorder
Interventions: XR-NTX+CM (Extended-Release Naltrexone plus Care Management); Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Idiopathic Parkinson's Disease, Parkinson Disease, Depression
Interventions: Transcranial Direct Current Stimulation; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Myopathy, Neuropathy, Glycogen Storage Disease Type II (Late-onset Pompe Disease)
Interventions: Observational study; Other
Lead sponsor: Duke University; Other
Eligibility: 12 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Alzheimer's Disease
Interventions: Psilocybin, Cognitive Training; Drug · Other
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 65 Years to 120 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Concussion, Brain, Mild Traumatic Brain Injury
Interventions: SCAT6, Visual/ Auditory Distraction; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Amblyopia
Interventions: iPad®, Patching 2 hours per day, 7 days per week; Device · Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 5 Years to 16 Years
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Rochester, Minnesota • Seattle, Washington

Conditions: Movement, Abnormal, Lower Extremity Problem
Interventions: Control HEP focusing on isometric gluteal activation, Experimental HEP focusing on isometric gluteal activation plus a movement retaining program; Other
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Stroke Hemorrhagic, Depression
Interventions: Fluoxetine, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 85 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: SCI - Spinal Cord Injury
Interventions: The Tethered Pelvic Assist Device (TPAD); Device
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma
Interventions: 9-ING-41, Irinotecan, Temozolomide, Cyclophosphamide, Topotecan; Drug
Lead sponsor: Actuate Therapeutics Inc.; Industry
Eligibility: Up to 22 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 9
States / cities: San Francisco, California • Aurora, Colorado • Chicago, Illinois + 6 more

Conditions: Glioma, Brain Cancer, Brain Tumor, Glioblastoma Multiforme, High Grade Glioma
Interventions: Dendritic Cell Vaccine, Tumor Lysate, Imiquimod, Leukapheresis; Biological · Other · Procedure
Lead sponsor: Edward Ziga; Other
Eligibility: 1 Year to 29 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Fabry Disease
Interventions: migalastat HCl; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 3
States / cities: Decatur, Georgia • New York, New York • Dallas, Texas

Conditions: Small-cell Lung Cancer, Brain Metastases
Interventions: 7t MRI; Device
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Parkinson's Disease, Sleep Disordered Breathing, Sleep Obstructive Apnea
Interventions: Neurocognitive function, Sleep evaluations; Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma

A Home Program Using Multimodal Sensory Feedback for People With Parkinson Disease

Brain Tumor Intraoperative Ultrasound Database

Sleep Architecture & Cognition in Focal Epilepsy

Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia

IntelliCare Study: Artificial Intelligence in a Mobile (AIM) Intervention for Depression

Improving Cardiovascular Risk Prediction Using Hand Held Carotid Ultrasonography Study

Mechanisms of Open and Hidden Placebo in Stroke Recovery

A Study of Patients With Fabry Disease (US Specific)

COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression

Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users

Exploring Mechanisms for Neuropsychiatric Symptoms of Parkinson Disease Using Transcranial Direct Current Stimulation

Identification of Tongue Involvement in Late-Onset Pompe Disease

Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin

The Effects of Environmental Distractions on SCAT6 Outcomes

Study of Binocular Computer Activities for Treatment of Amblyopia

Gluteal Activation Plus Movement Retraining

Poststroke Depression in Hemorrhagic Stroke

TPAD for Recovery of Standing After Severe SCI

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors

Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study

7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)

Sleep Disordered Breathing and Its Impact on Neuro-cognitive Performance and Quality of Life in Parkinson Disease